Phase 2 Study of Talazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced Urothelial Carcinoma

The primary objective of this study is to evaluate the efficacy of **talazoparib** and **avelumab** as maintenance therapy in patients with platinum-sensitive metastatic or locally advanced **urothelial carcinoma**. This is clinically relevant as it aims to improve outcomes in a patient population with limited treatment options following initial platinum-based chemotherapy. The study seeks to determine whether this combination can extend progression-free survival and overall survival, providing a potential new therapeutic strategy for this challenging condition.

The clinical trial involves participants diagnosed with **locally advanced/metastatic urothelial carcinoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been disclosed. The trial aims to evaluate maintenance treatment in the specified patient group.

The clinical trial is designed to evaluate the efficacy of **maintenance treatment** in patients with locally advanced or metastatic urothelial carcinoma. This is a single-arm, Phase 2 trial, which is not randomized or controlled, and it aims to assess the therapeutic potential of the investigational regimen. The trial commenced recruitment on January 25, 2021, and is projected to conclude by December 31, 2025. Participants will be involved in the study for the duration of the trial unless specific conditions necessitate early termination, such as adverse events or withdrawal of consent.

The sequence of study visits begins with an inclusion visit, where potential participants undergo screening to determine eligibility based on predefined criteria. Following successful enrollment, participants will attend regular follow-up visits, which are scheduled to monitor the safety and efficacy of the treatment regimen. These visits will include assessments such as physical examinations, laboratory tests, and imaging studies as required. The end-of-study visit marks the conclusion of the participant's involvement, where final evaluations are conducted to gather comprehensive data on the treatment outcomes.

Participants are expected to adhere to the study protocol throughout their involvement. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or voluntary withdrawal by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements to ensure the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under Phase 4, indicating it is conducted after the approval of the treatment to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. The trial is scheduled to conclude by December 31, 2025, with recruitment having commenced on January 25, 2021. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical assessments in Phase 4 trials may include monitoring symptom improvement, biomarker levels, or disease remission rates. The methods for measuring and analyzing these parameters are expected to adhere to validated clinical practices and may involve the use of standardized scales, laboratory tests, or patient-reported outcomes. The trial's design and execution will follow rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy data collected.